1064 / 1068
PEMBROLIZUMAB TRIAL SCHEMA
ANAL CANCER
D1
MITOMYCIN
12MG/M2
+ either
5FU 1G/M2
D2-5, D29-32
(incl)
or
CAPECITABIN
E
825MG/M2
ON DAYS OF
RT
Day 15
CRT
Day 22
CRT
Day 29 CRT
Day 1 CRT
Day 8 CRT
ANAL CANCER
D1
MITOMYCIN
12MG/M2
+ either
5FU 1G/M2
D2-5, D29-32
(incl)
or
CAPECITABIN
E
825MG/M2
ON DAYS OF
RT
Day 15
CRT
Day 22
CRT
Day 29 CRT
Day 1 CRT
Day 8 CRT
ANAL CANCER
D1
MITOMYCIN
12MG/M2
+ either
5FU 1G/M2
D2-5, D29-32
(incl)
or
CAPECITABIN
E
825MG/M2
ON DAYS OF
RT
Day
15
CRT
Day 22
CRT
Day 29 CRT
Day 1 CRT
Day 8 CRT
Follow up – 3 months toxicity check + MRI at 6 and 12 months
Day 50
CRT
Day
57 CRT
Day 64 CRT
Day 36 CRT
Day 43CRT
Day 50
CRT
Day 57
CRT
Day 64 CRT
Day 36
CRT
Day 43
CRT
Day 50
CRT
Day 57
CRT
Day 64 CRT
Day 36 CRT
Day 43 CRT
Pembrolizumab
200mg
q21d
Key
COHORT 1
COHORT 2
COHORT 3